159 related articles for article (PubMed ID: 21963870)
21. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
[TBL] [Abstract][Full Text] [Related]
22. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
24. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
25. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
26. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
29. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
Kumar S; Collins W; Egan A; Yadava A; Garraud O; Blackman MJ; Guevara Patino JA; Diggs C; Kaslow DC
Infect Immun; 2000 Apr; 68(4):2215-23. PubMed ID: 10722622
[TBL] [Abstract][Full Text] [Related]
31. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.
Kumar S; Villinger F; Oakley M; Aguiar JC; Jones TR; Hedstrom RC; Gowda K; Chute J; Stowers A; Kaslow DC; Thomas EK; Tine J; Klinman D; Hoffman SL; Weiss WW
Immunol Lett; 2002 Apr; 81(1):13-24. PubMed ID: 11841841
[TBL] [Abstract][Full Text] [Related]
32. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
Mazumdar S; Mukherjee P; Yazdani SS; Jain SK; Mohmmed A; Chauhan VS
Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832
[TBL] [Abstract][Full Text] [Related]
33. An engineered Plasmodium falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed to malaria.
Bisseye C; Yindom LM; Simporé J; Morgan WD; Holder AA; Ismaili J
Clin Exp Immunol; 2011 Dec; 166(3):366-73. PubMed ID: 22059995
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
Weiss R; Gabler M; Jacobs T; Gilberger TW; Thalhamer J; Scheiblhofer S
Vaccine; 2010 Jun; 28(28):4515-22. PubMed ID: 20438877
[TBL] [Abstract][Full Text] [Related]
35. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.
Nwuba RI; Sodeinde O; Anumudu CI; Omosun YO; Odaibo AB; Holder AA; Nwagwu M
Infect Immun; 2002 Sep; 70(9):5328-31. PubMed ID: 12183594
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
[TBL] [Abstract][Full Text] [Related]
38. A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.
Tetteh KK; Conway DJ
Vaccine; 2011 Oct; 29(44):7811-7. PubMed ID: 21820475
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
Cherif MS; Shuaibu MN; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Tsuboi T; Sasaki H; Hirayama K
Vaccine; 2011 Nov; 29(48):9038-50. PubMed ID: 21939717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
